Pressure Biosciences Inc (PBIO)

[noshorthere]

It should be remembered that this Company continues to ignore selling their "product" to customers, and continues to exclusively spend money trying to attract investors. Not a good thing for business growth.

About New to the Street:
“The TV program provides the CEOs or executives of a company with a platform to explain to the audience about their company, their product, goals, roots, visions, and more. ….This gives a potential investor lot of data and information helping them decide whether they want to invest in the company and its product or not.”

From the disclaimer portion of their website (New to the Street):
“It should be understood that companies (clients) on the show pay a minimum of $350,000 for a 12 Part Series that guarantees over 60 Linear Television Broadcasts on multiple networks and over 70 commercials per quarter ( 3 month period) There is also monthly production fees charged averaging $5000 per month.”

[Louied91]

$PBIO Pressure BioSciences Updates Forecast with Six Key Goals for June 2023 with Expected Multi-Million Dollar Growth Increments in FY 2023 and Beyond

https://www.accesswire.com/758611/Pressure-BioSciences-Updates-Forecast-with-Six-Key-Goals-for-June-2023-with-Expected-Multi-Million-Dollar-Growth-Increments-in-FY-2023-and-Beyond

SOUTH EASTON, MA / ACCESSWIRE / June 1, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a global leader in the development and sale of broadly enabling, high-pressure-based equipment, consumables, and specialty testing services to the worldwide biotherapeutics, nutraceuticals, cosmeceuticals, food and beverage, and other industries today highlighted the six key goals they expect to achieve during the month of June 2023, and discussed the significant financial impact expected to result for the Company in FY 2023 and beyond. The top six goals expected to be completed in June include:

1. Addition of Three $1M+ (Annual) Nano-CBD Commercial Distribution Contracts

Leading Retailer (CBD Supply MD) recently introduced NanoBloom CBD to their multi-state client base.
PBI believes the Agreement with CBD Supply MD will be worth $1.5M+ over the next 12 months.
PBI anticipates three additional CBD retailers with similar revenue potential to close during June 2023.
2. Sale of Two Licenses ($1M+) for PBI's Patented UltraShear™ Platform for Nano-THC Processing

Multiple groups are negotiating a possible purchase of a 3-year exclusive THC processing license for a state.
PBI anticipates the sale of two exclusive licenses to close during June 2023.
PBI expects most license sales to generate - on average - about $1M in up-front fees.
3. Completion of Third (and Largest) Consumer Focus Group on Nano-THC

Two focus groups have validated the market transforming speed and dosing efficiency of PBI's Nano-THC.
Third focus group expected to further validate these results, plus super-fast pain relief from topical use.
4. John Westlake, Canopy CBD Farms ("CCF"), to Launch as Master Distributor of Nano-Cannabis Products

Assumes heightened role as a master distributor of PBIO nano-cannabis products in June 2023.
John/CCF delivers multiple sales channels, a deep nationwide industry network, and access to media and capital.
5. Initial Production Runs in PBIO's New Strategic Manufacturing Facilities

PBI's severe capacity limitations in current production facilities become relieved with new expansion transition into strategic partner Artisan Industries facilities, only 6 miles from PBI headquarters.
6. Dr. Denese Skin Science Collaboration Completes First Retinol Product R&D Phase - Expects Marketing LOI

Retinol-based anti-aging creams and serums are among the Dr. Denese Skin Science top sellers on QVC.
Dr. Denese believes PBIO's UltraShear nanoemulsification technology is the enabling platform for a revolutionary new generation of skincare.
PBI has completed the development of UltraShear-processed retinol with lipid-soluble Vitamin C formulations.
PBI anticipates a formal product marketing Letter-of-Intent (LOI) on these products with Dr. Denese in June.
Mr. Richard T. Schumacher, PBIO's President and CEO stated: "We have been laser-focused on making measurable progress on those areas that offer the best potential for rapid recurring revenue growth in the near future. I am pleased to say that the PBI Team has been highly successful in these endeavors. Progress on the six goals delineated here is a testament to their hard work and effectiveness - and to the value proposition of our UltraShear platform. All told, the incremental annual revenue expected from these goals, which our team expects to complete in June, should exceed several millions of dollars during the second half of FY 2023 alone, with incremental revenues growing further in FY 2024 and beyond."

Mr. Schumacher concluded: "We have accomplished a great deal in product development, technology demonstrations, and early commercial traction over the past year - and we believe that PBIO is highly undervalued at current market prices. We are continuing to help current and future investors understand the enormous potential of our many assets, especially our revolutionary (and diversely patented) Ultra Shear nanoemulsions technology platform."

[Louied91]

New to The Street Signs Pressure BioSciences, Inc. To 12 Month TV Series, Agreement Includes Commercials and Billboard Ads

https://www.globenewswire.com/news-release/2023/06/01/2680506/0/en/New-to-The-Street-Signs-Pressure-BioSciences-Inc-To-12-Month-TV-Series-Agreement-Includes-Commercials-and-Billboard-Ads.html

NEW YORK, June 01, 2023 (GLOBE NEWSWIRE) -- FMW Media's business TV show, New to The Street, announces the signing of a 12-month contract for filming and broadcasting tailored interviews and commercials about Pressure BioSciences, Inc. (OTCQB: PBIO) ($PBIO).

New to The Street’s TV anchors will interview the management team at PBIO with each show airing on New to The Street's televised syndicated outlets on Newsmax and Fox Business Network, sponsored program on Bloomberg TV, and website www.newtothestreet.com.

Pressure BioSciences, Inc. develops and sells innovative extreme pressure-based platform technology solutions for the global life sciences industry. The Company generates revenues from its patented platforms: Pressure Cycling Technology (“PCT™”), BaroFold™ Platform, and Ultra Shear Technology (“UltraShear™” or “UST™”).

With over 300 PCT installations worldwide, their Who’s Who of blue-chip customers spanning industry, academia and government are using PBIO products for vaccine developments, soil/plant biology applications, biotherapeutics, and diverse other life sciences applications. A wide array of scientific key opinion leaders underpins their credibility as their new UltraShear technology launches a new era of delivering oil-based nutrients and therapeutics, invisibly solubilized as nanoemulsions of oil in water.

The New to The Street’s social media team and television network partners will re-share media content, creating a platform to increase awareness about PBIO. All broadcasted shows will stream on the New to The Street website, www.newtothestreet.com. On a schedule, show previews and commercial ads will air on selected New to The Street syndicated and sponsored TV platforms. Digital ads will stream on New to The Street's billboard platform throughout New York City.

Richard T. Schumacher, President/CEO of Pressure BioSciences, Inc., states, “I look forward to appearing on New to The Street, to share our Company’s business success stories with viewers. PBIO commercializes its patented technologies to create and deploy products that are uniquely transformative in their markets. We are particularly excited about our UltraShear platform, now poised for explosive growth as a game-changer to the basis of competition across multiple diverse major markets. During each show, the objective will be to inform viewers about the Company growth strategies, current/ future products, and expected opportunities.”

TV viewers will hear about more about PBIO’s patented technologies, from PCT using alternating cycles of hydrostatic pressures to control biomolecular interactions and facilitate unprecedented scientific outcomes, to BaroFold controlling the critical refolding of proteins into active configurations for biopharmaceuticals, to UltraShear’s breakthroughs in speed and completeness of payload delivery across pharmaceuticals, nutraceuticals, cosmeceuticals, food/beverages, agrochem and other markets. Their platforms are gaining worldwide recognition, with customers daily increasing usage of their products from biomarker discovery to biopharmaceutical production to revolutions in treatment, nutrition, health and beauty.

Vince Caruso, CEO / Producer of New to The Street, states, "I am excited in having PBIO on the show for a 12-part TV series. They have patents, products, and a dedicated team that I believe our viewers will enjoy learning more about. With recognized scientific peer-reviewed publications about the Company’s products, and worldwide sales, the Company is positioned for a strong growth trajectory. The PBIO storyline is compelling, and I'm excited for the New to The Street audience to learn more about the Company."

New to The Street's TV interviews with Pressure BioSciences, Inc.’s management, airing on Newsmax (syndicated), Fox Business Network (syndicated), and Bloomberg TV (sponsored) "To Be Announced."

[Louied91]

$PBIO Pressure BioSciences Announces Commercial Availability of Best-in-Class Nano-CBD Topical Spray, Featuring Lightning-Fast Action from PBI's UltraShear Processing

https://www.accesswire.com/756357/Pressure-BioSciences-Announces-Commercial-Availability-of-Best-in-Class-Nano-CBD-Topical-Spray-Featuring-Lightning-Fast-Action-from-PBIs-UltraShear-Processing

Leading CBD Retailer (CBD Supply MD) Today Introduces the "NanoBloom CBD" Topical Spray Through Their Mid-Atlantic Store Chain and Their Highly Effective, Nationwide, On-Line Retail Store

SOUTH EASTON, MA / ACCESSWIRE / May 22, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a global leader in the development and sale of broadly enabling, high-pressure-based equipment, consumables, and specialty testing services to the worldwide biotherapeutics nutraceuticals, cosmeceuticals, food and beverage, and other industries, and CBD Supply MD, one of the largest and best-known retail suppliers of CBD products in the multi-state mid-Atlantic region, today announced the commercial introduction and availability of their "NanoBloom CBD" Topical Spray, a leap forward in best-in-class, super-fast acting, highly bioavailable hemp-derived, all natural, CBD Topical Spray, also delivering rock solid multi-year stability.

NanoBloom CBD was formulated for ideal speedy effectiveness and optimal potency, finally addressing and resolving consumers' primary unmet objectives for CBD topical applications. In addition to its speed of action and potency breakthroughs, NanoBloom CBD is believed to be the only pharma-grade, preservative-free, all natural, Nano-CBD product available in the U.S. today, if not the world. The distribution agreement between the companies is for a minimum of two years and is expected to generate over $1.5 million in revenue for PBIO in the first year alone.

Mr. Keith E. Manley, Co-founder of CBD Supply MD, commented: "We are utterly thrilled and honored to introduce the first Ultra Shear Technology™ (UltraShear™ or UST™) processed product to the open market nationwide. Academic bioavailability data and consumer focus group feedback has convincingly demonstrated that PBIO's revolutionary UltraShear platform generates nanoemulsions of unmatched fast and complete bioavailability and long-term shelf stability, presenting a value proposition that is unparalleled in the industry. We are certain that the NanoBloom CBD product is destined to become a true game-changer. Happily, this is the first of many UltraShear nanoemulsified products we plan to bring to market with our new partner PBIO. As excited as this is for me personally and our CBD Supply MD team, I know our enthusiasm will pale in comparison to the benefits our customers are about to receive and understand."

Mr. John B. Hollister, Director of Sales and Marketing at PBIO, said: "CBD Supply MD is a highly respected market leader, with one of the largest established customer bases in the mid-Atlantic region, and with nationwide reach through their highly-effective website. We are excited that their customers will now have the opportunity to benefit from a best-in-class, UltraShear Nano-CBD product - in their NanoBloom CBD Topical Spray. We look forward to developing multiple additional product formulations with CBD Supply MD beyond this initial but substantial $1.5M CBD product agreement."

Mr. Richard T. Schumacher, PBIO's President and CEO summed up: "Our diverse work on UltraShear nanoemulsion processing across nutraceutical, cosmeceutical, pharmaceutical, agrochemical, and food/beverage markets has generated an exciting array of developing commercial opportunities for PBI. We are excited to announce initial commercialization with CBD Supply MD - and grateful to have the opportunity to work with such a highly respected retail sales leader in CBD products and the broader cannabis marketplace. We are negotiating with multiple companies interested in rights to our UltraShear processed nanoemulsion products and expect to announce a number of additional supply agreements in the coming weeks. All told, we expect that revenue from UltraShear processing in 2023 will quickly diversify across multiple major opportunities in nutraceuticals, cosmeceuticals and beyond, far exceeding revenue from all other PBIO products."

[Louied91]

$PBIO Pressure BioSciences, Inc. Q1 2023 Financial Results Achieve All-Time Quarterly Record

https://www.accesswire.com/755225/Pressure-BioSciences-Inc-Q1-2023-Financial-Results-Achieve-All-Time-Quarterly-Record

Validated Nanoemulsion Capabilities Are Transformative Across Multiple Major Markets, New $1.5M Contract, New Manufacturing Facility, and Reduced Cash Burn Set Stage for Expected Strong FY 2023

Investor Call Scheduled for Tuesday May 16, 2023 at 4:30 p.m. ET

SOUTH EASTON, MA / ACCESSWIRE / May 16, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a leader in the development and sale of broadly enabling, high pressure-based equipment, consumables, and specialty testing services to the worldwide biotherapeutics, nutraceuticals, cosmeceuticals, food & beverage, and other industries, today reported that record quarterly financial results for any fiscal quarter was achieved in the first quarter ended March 31, 2023. The Company also provided a business update and offered guidance for expected pivotal achievements through 2023.

Financial Highlights: Q1 2023 vs. Q1 2022 (rounded to nearest hundredth, except EPS)

Total revenue for Q1 2023 was $740,600, an increase of 54% from $480,000 for Q1 2022.
Instrument sales for Q1 2023 were $427,500, an increase of 74% from $245,600 for Q1 2022.
Consumable sales for Q1 2023 were $66,400 compared to $40,000 for Q1 2022, an increase of 66%.
PBI Agrochem sales for Q1 2023 were $130,700 as compared to $83,300 for Q1 2022, an increase of 57%.
Operating loss for Q1 2023 was $3,637,700 compared to $1,086,300 for Q1 2022. This increase in operating loss was due to a non-cash expense of $1,480,900 for stock and warrant issuances to debt holders/professional services groups and to a non-cash expense of $1,430,200 for equity-based compensation awards.
Cash used from operations in Q1 2023 was $422,200 as compared to $756,300 in Q1 2022, a decrease of 44%.
Basic and diluted net loss per share was $(0.46) for Q1 2023, a decrease from $(0.48) from Q1 2022.
The Company reduced its cash burn from operations by 44% YoY to just $422,000 in the first quarter 2023, reflecting our ongoing focus on disciplined cash management. During Q1 of 2023, the Company issued several one-time stock issuances to certain debt holders and investor relations firms, to assist with critical corporate financing and development initiatives and public and private investor development. Management is confident that these investments will assist in focusing investor attention on our pivotal progress, as we proceed through commercialization of our UltraShear platform. During the quarter, the Company also issued stock options to employees and directors for the first time since 2019, recognizing the importance of incentive compensation in the retention of critical staff. The awards were issued at an above-market exercise price.

Q1 2022 and Recent Operational and Technical Highlights

May 9: Extended Consumer Testing Strongly Validates UltraShear Market Transforming Speed/Dosing Efficiency.
April 26: Company Updates Rapid Progress on Limited Offering of Exclusive UltraShear THC Licenses.
April 18: PBIO Announces Expansion into Strategic Manufacturing Facilities.
March 28: PBIO Reports Fresh Sales Momentum for PBI Agrochem.
March 22: PBIO Receives $1.5 Million Contract for UltraShear™ Nanoemulsified CBD.
March 1: Company Announces Exchange of Over $10 Million of Debt into Equity.
Feb 1: PBIO Receives Record Nearly $600,000 Single Order for 16 PCT Instruments.
Jan 27: PBIO and One World Products Announce Partnership in CBD-Nanoemulsion Sports Performance Drink.
Mr. John B. Hollister, Director of Marketing and Sales for PBIO, commented: "During the first quarter of 2023, the PBIO Team were terrifically effective in setting the stage for what we expect to be a year of rapid revenue growth, with significant expansion of both our customer base and product listing, strengthening of our financial framework, and recognition of our revolutionary UltraShear technology as the best-in-class nanoemulsion processing platform worldwide."

Mr. Richard T. Schumacher, President and CEO of PBI, stated: "Our anticipated ramping and expansion of UltraShear commercialization activities is now underway. We plan to ship the first production batch of Nano-CBD to our Maryland distributor for commercial sale within a week. The second batch - to a distributor in Massachusetts - should follow before the end of May. In addition, we have achieved important progress in the development of the next generation of anti-aging skincare, with our successful high quality nanoemulsification of oil-based retinol. We continue to progress smoothly towards our announced goal of developing several high-impact, market-changing products with extraordinarily potent bioavailability that we believe have never been available or commercialized until now: nanoemulsified hair replacement products, nanoemulsified immune booster products, and nanoemulsified sleep enhancement products. To our team of investors and employees, we share gratitude and anticipation over this exciting time to be a PBIO shareholder!"

[MaunawiliBoy]

If I wanted to send a man to the moon, I would want a cohort of scientists and engineers. If I wanted to evaluate the effectiveness of UST nano emulsion THC, I would want a cohort of (as you labeled them) potheads and not a group of scientist or engineers.

[noshorthere]

Yes, it was. Not to be confused by a round-table discussion by weed-heads, conducted by a weed-dealer, as being even close to a scientific discovery or achievement.

"Man, gimme a hit of that, huh. That's some good shit."

[MaunawiliBoy]

no SHORT here
Really?

So, the mission to land a man on the moon was not a cohort of like-minded scientist and engineers?

[noshorthere]

Cohort: A group of like-minded people sharing common characteristics.

No legitimate study EVER uses a cohort group. Not only do you not get any valid info from a "cohort", but the focus group was done by a cannabis marketing company.

[Louied91]

$PBIO Pressure BioScience’s Pressure-Based Tech Is Ready To Spur Innovation And Growth In A Life Sciences Sector In Flux

https://www.accesswire.com/753930/Pressure-BioSciences-Pressure-Based-Tech-Is-Ready-To-Spur-Innovation-And-Growth-In-A-Life-Sciences-Sector-In-Flux

[Louied91]

$PBIO Extended Consumer Testing Strongly Validates Market Transforming Speed and Dosing Efficiency of Pressure BioSciences UltraShear Processed Nano-THC Oral Spray

https://www.accesswire.com/753697/Extended-Consumer-Testing-Strongly-Validates-Market-Transforming-Speed-and-Dosing-Efficiency-of-Pressure-BioSciences-UltraShear-Processed-Nano-THC-Oral-Spray

Additional Focus Groups Corroborate UltraShear Nano-THC Produces Equal to Much Better THC Experiences, Even from Lower THC Dosing Levels; Also, Lightning-Fast Pain Relief from Topical Use.

SOUTH EASTON, MA / ACCESSWIRE / May 9, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or "Company") today announced results from additional consumer focus group testing of a THC Nanoemulsion Oral Spray designed for rapid, direct absorption through the cheeks. The THC Nanoemulsion Oral Spray was prepared using PBI's revolutionary Ultra Shear Technology™ (UltraShear™) platform by PBI's California-based partner companies, including Crème De Canna (CdC), a CA-licensed manufacturer and long-established provider of innovative, high-quality cannabis products.

Additional consumer focus group testing more than doubled the original cohort of participants and has strongly affirmed multiple pivotal results on the UltraShear processed Nano-THC Oral Spray being powerfully differentiated from traditional THC dosing alternatives:

Speedy onset of first effects (average well under ten minutes - many reports in first few minutes) versus typical THC edibles requiring 30-60 minutes.
Much faster progression to maximum effects (average well under 40 minutes - many reports in 30 minutes or less) versus typical THC edibles requiring 60-120 minutes.
Eliminates health issues associated with smoking or vaping.
Enormous efficiency improvement in dose payload delivery allows equal to much better/greater THC experience from dosing down to a small fraction of user's normal dosing levels.
Stable, all plant formulation is sterile packaged with no added preservatives.
Multiple testers applied even a single spray to painful body areas and reported fast to instant transdermal pain relief.
Mr. John B. Hollister, PBIO's Director of Sales and Marketing, discussed highlights from the studies: "Most testing participants used lower doses of UltraShear Nano-THC than their usual dose level for THC products - and the vast majority of volunteers reported the same, more, or much more effect from the lower dosing of Nano-THC versus their normal dosing choices. Multiple normally heavy users of THC and many other participants reported onset of effects from the Nano-THC Oral Spray very quickly, even at significantly lower THC concentrations than usually consumed."

Mr. Hollister continued: "Following completion of the oral spray studies, we were also delighted by unplanned outcomes from multiple participants spraying the Nano-THC onto bodily pain locations (joint, arthritis, soreness, etc.) - and reporting very rapid, nearly instant relief from localized pain. All of these reported results are unsurprising to us, as scientific literature has long documented the greatly increased bioavailability of water-insoluble valuable constituents when dissolved into sufficiently small (under 100 nm) oil droplets. PBI's UltraShear platform accomplishes this with unmatched uniformity, tunable droplet size control, lower cost of production, better ease-of-use, and long-term stability."

Mr. Richard T. Schumacher, President and CEO of PBIO, concluded: "These extended study results have confirmed the potential for a market transformation in THC consumption with a new oral/transdermal dosing modality in between the existing smoke/vape and edible food/beverage bifurcation of this enormous market. We believe that the customer experience with UltraShear processed Nano-THC will be compelling to drive a tidal change in the market, with potential explosive adoption of UltraShear processed Nano-THC."

Mr. Schumacher continued: "We are experiencing similar reactions and developments as we work with early partners across multiple other markets in nutraceuticals, cosmeceuticals, food/beverage, and more. 2023 is poised to be a watershed transformational year for PBI, as we capitalize for roll-out of the UltraShear platform and converge upon our announced NASDAQ or NYSE uplisting goal."

[MaunawiliBoy]

There are two revenue streams they are working on. Tolling and licensing UST. We'll see where this story goes in about a month. Q1 FY23 should be out soon.

[noshorthere]

First, they didn't just open up licensing a week ago----they announced it April 21, and posted an update April, 26. If; you think that companies will jump all over themselves to pay $1M for a 3 year license to produce/sell in only one State, and not own the equipment, when they can own the equipment and do what they want with it for ass long as they want, and for a very tiny fraction of the cost, you need to start thinking about Lotto and give up on equities.

Second, I'm not surprised that you haven't seen any dilution since you've been invested in PBIO. You're in love with the stock/company. In the 10k they had 13.6 million common shares on Dec. 31. They now have over 19 million common shares after just over 4 months. The debt for equity swap was “preferred” shares---not common shares. That's some serious dilution, and it's all because the company doesn't generate the cash needed to pay their debts and interest. So, you think that stock dilution to fund the company has not been their MO, huh? There are two ways to fund a company via stock dilution. 1) Have an ATM, and 2) trade common stock for debt/interest. PBIO uses #2.

Thirdly, I assume that you are pointing out, in error, that PBIO doesn't use surfacants or emulsifiers, but others do. Wrong again. Surfacants and emulsifiers are used to keep drops of ANY SIZE from coalescing when they come in contact with each other. Some emulsions need them, and other emulsions may not, and it has nothing to do with whether they are made with ultrasound or high pressure pump/valve. Industrial Sonomechanics has been selling their ultrasound nano-emulsifier for 6-7 years, and have had the time, and inclination, to develop their own as an OPTION, just as chillers are an OPTION. PBIO has yet to commercialize their UST equipment (the $75K Safer Medical order being the exception) .

You really need to 1) read, 2) understand, 3) think, before you post.

"Never fall in love with a stock; always have an open mind.".... Peter Lynch
“Never fall in love with a stock---rent the bitches---they might have the clap.”....Me

[MaunawiliBoy]

Sonomecnanics not the same.......

Customers who would like to produce translucent nanoemulsions of lipophilic (oil-soluble) bio-active compounds, such as cannabis extracts (a.k.a. water-soluble CBD and THC), vitamins, essential oils, terpenes, nutraceuticals and pharmaceuticals, but do not have the capability or desire to develop their own formulations and processing procedures can take advantage of our all-in-one NanoStabilizer®-LT. This proprietary blend of food-grade (GRAS) carrier oils, EMUSIFIERS, and preservatives (all derived from natural sources) is designed to work with ISM laboratory, bench and industrial ultrasonic processors and comes with step-by-step processing instructions. NanoStabilizer®-LT has no taste of its own and makes it possible to easily and quickly produce highly translucent, permanently stable and fully water-compatible nanoemulsions with median droplet sizes in the range of 10 – 50 nanometers.

[MaunawiliBoy]

PBIO opened up UST licensing a week ago. Per the PR it will take 15 to 60 days to close all 5 license agreements. I have not seen any significant dilution of shares over the time I have invested in PBIO. I think the leadership is very responsible in this regard. Yes, there was a 1:30 reverse split several years ago and the recent conversions of debt to equity. I think when PBIO is listed on a major exchange they will issue new shares to fund growth as necessary. What growth company doesn't do this? Stock dilution to fund the company has not been their MO. I see a new name added into the sales/marketing department as a contact for the UST licensing process.

[noshorthere]

Check their PR's again. They haven't sold any licenses yet. If they ever do, you can count on an 8K filed over it because it would be an "honest" material event.

[noshorthere]

If you were to watch the Industrial Sonomecnanics video you would see that in batch mode the medium runs closed loop through a chiller and back to the probe until the drops are, or nearly are, the same size. To not run in batch mode you just run open loop through the right number of daisy-chained systems to accomplish the same thing---only higher volume.

The problem with most of the loyal followers is you don't do your own research and believe everything that the CEO of a company of twelve tells you. I was once a VP of Sales and Marketing (for a very short time) of another very small public company that produced high dollar, high tech, capital equipment. I was fired before our annual shareholders meeting because I refused to lie to, or mislead, the shareholders. That company only focused on selling stock.

[MaunawiliBoy]

Yes, you are correct. However, the ultrasound method does not produce homogenous droplet size as with UST. Yes, it will produce nano droplet sizes along with larger sizes within the same batch. Batch process means it is not a continuous flow process.

[Belgium 69]

Hi, that's all possible but PBIO was the smartest to sell it through license contracts, Q1 will prove it + Q2 + Q3 enz; so they weren't that stupid.
And it is possible that pressure-based nano-emulsions have advantages over ultrasonic-based nano-emulsions.

[noshorthere]

They have not developed a new mousetrap. They have only created a much more expensive and complicated mousetrap. There has been ultrasound nano-emuslifiers working for at least 6 years---producing droplets as small as 20nm. One, Industrial Sonomechanics builds and sells them at a small fraction of the cost ($60K vs $200K), and has been contract manufacturing (like tolling) for more than a year. I'm not sure these clowns even understood their market niche when they acquired the Baro-bs.

[Belgium 69]

PBIO has so much potential in different markets like protein, THC, food etc etc.
If this stock comes into the picture very soon it will be unstoppable and it will get the right attention from the right people (also new ones)

[MaunawiliBoy]

I'm bullish on this company in spite of their so-called incompetence as others have described. Yes, they are a bunch of MIT, Harvard, and Stanford geeks who developed a new mousetrap. Actually, three new mouse traps. One of which they purchased from another company. However, I believe there is significant commercial interest in the UST platform. I have personally sampled UST processed CBD sourced from two different companies. It is transparent and it is water soluble. It dilutes instantaneously in water. The range of applications for this process is TBD, but already they are simultaneously gaining traction in several markets. Cash strapped, yes. However, the THC/CBD industry have lots of free flowing green cash. Installing UST equipment in legal states makes great sense by getting around Federal interstate trafficking regulations.

Nice to see other contributors on this board.

[Wildcard]

This “2.50” means diddly squat you don’t understand how this works.
If he can’t pay the notes back in time when they mature it all gets converted into stock plus Interest then it gets diluted. It’s a fancy way of doing a reverse toxic note. Looks good on paper, bad for stock price.
That’s why OS went from 10mill to 15mill in the span of a couple months when they came due. That “2.50” is just for show.

[noshorthere]

Most of these worthless penny stock companies have a reverse-split followed by an ATM to raise cash to pay bills and dilute. PBIO had a 30:1 reverse split in 2017, but doesn't appear to have done an ATM to raise cash. They paid bills by borrowing then paying back with shares, and thus diluting. Different approach----same end result---dilution and lower price. These clowns have absolutely no idea how to grow their business. They have made three business pivots in the last three years----and none of them well thought out.

[Louied91]

$PBIO Pressure BioSciences Updates Rapid Progress on Limited Offering of Exclusive THC Licenses for Revolutionary UltraShear Nanoemulsion Processing Platform

https://www.accesswire.com/751316/Pressure-BioSciences-Updates-Rapid-Progress-on-Limited-Offering-of-Exclusive-THC-Licenses-for-Revolutionary-UltraShear-Nanoemulsion-Processing-Platform

Company Confirms Initial Negotiations Underway with Five Different Groups for Single Statewide Exclusive Licenses for Nano-THC Products

SOUTH EASTON, MA / ACCESSWIRE / April 26, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a global leader in the development and sale of broadly enabling, high-pressure-based equipment, consumable products, and specialty services to the life sciences, nutraceuticals, cosmeceuticals, and other industries today provided a progress update on their exciting April 21, 2023, announcement. On that day, the Company announced their strategic decision to offer up to five exclusive statewide THC-processing licenses to their revolutionary, patented UltraShear Technology™ (UltraShear™ or UST™) platform for the preparation of oil-soluble THC concentrates into long-term stable, effectively water-soluble, and highly bioavailable nanoemulsions of THC oil in water.

THC is an oil-soluble molecule known to be quickly absorbed when inhaled (nearly instantaneous first effects) but is slowly absorbed and poorly bioavailable when ingested (30-60 minutes to first effects, and 60-120 minutes to full effects, on average). Data generated by PBIO's independent collaborators and academic research sources show that ingestion of THC oil pre-processed by the UltraShear platform evidenced first effects in an extremely rapid 1-10 minutes (3-5 minutes on average). In addition, UltraShear CBD nanoemulsions have shown long-term stability, effective water solubility, and high total bioavailability in independently-run animal studies. Early testing of Nano-THC preparations is already confirming similar rapid and effective absorption in line with the Nano-CBD results.

Following closure of each license purchase, the Licensee becomes the exclusive producer of UltraShear THC nanoemulsions within their designated licensed state for a three-year period. Critical terms of each exclusive license include:

License applicable for nanoemulsification of THC as the primary active ingredient.
One license per state: all states are currently available but will not be available upon closure of the first five licenses.
THC products can only be shipped within the state of license.
Licensee pays an upfront license fee to PBIO.
Licensee pays upfront for the manufacture of a custom-designed UltraShear instrument for their facility.
The final cost of the license and the UltraShear instrument will be negotiated between Licensee and PBIO.
Licensee will have a zero-cost instrument lease for three years post-instrument commissioning.
Licensee will have a first right to negotiate an extension to exclusivity when the three-year exclusive period ends.
Based upon the strong and diverse initial response to this opportunity, the Company believes it will close on the sale of all five licenses within the next 15-60 days. Additional parties interested in participating in this Nano-THC Exclusive and Early Access Program should contact John Hollister or Ken Micciche at 508-230-1828.

Mr. Richard T. Schumacher, CEO and President of PBI, summed up: "Completing the sale of these five licenses is expected to generate $5,000,000 or more of topline, non-dilutive revenue for PBIO. These funds will facilitate our rapid production of UltraShear equipment, which will support these THC processing licenses, as well as efforts underway to develop multiple other Nano products to serve additional major potential markets, such as sleep, immune booster, and hair restoration. Many of these additional markets are multiples in size of the THC opportunity, which is already a major market opportunity."

[MaunawiliBoy]

The company maintained very low float for a very long time and accumulated debt. I think it's a good move to convert debt into equity. The last conversion rate was very attractive for shareholders at $2.50/shr. Time to move the company onto the big board. In order to do that debt has to be reduced and increase revenue. Revenue will be stalled until they get their new facility at Artisan up and running. Cross our fingers.

[Wildcard]

He needs to leapfrog all his toxic notes that he keeps issuing stock for

[Wildcard]

Lots and lots of dilution from his notes

[bcblbrbm]

With all this great company info posted here in the past two months, how come the pps is down approximately 40% in the same two months?

[Louied91]

$PBIO Pressure BioSciences Unveils Powerful THC Market Leapfrog Opportunity with Exclusive Licensing of Their Revolutionary UltraShear Nanoemulsion Processing Platform


https://www.accesswire.com/750615/Pressure-BioSciences-Unveils-Powerful-THC-Market-Leapfrog-Opportunity-with-Exclusive-Licensing-of-Their-Revolutionary-UltraShear-Nanoemulsion-Processing-Platform

Limited Window for Exclusive 3-Year Statewide Licenses for THC Processing.
PBI's UltraShear Platform Delivers Unprecedented Dosing, Speed, Stability, and Reliable Precision Without Inhalation Health Issues.

SOUTH EASTON, MA / ACCESSWIRE / April 21, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a global leader in the development and sale of broadly enabling, high-pressure-based equipment, consumable products, and specialty services to the life sciences, nutraceuticals, cosmeceuticals, and other industries today announced the Company's strategic decision to offer up to five exclusive licenses to their patented and powerful UltraShear Technology™ (UltraShear™ or UST™) platform for the processing of oil-soluble THC concentrates in water into long-term stable, effectively water-soluble, and highly bioavailable nanoemulsions.

THC is an oil-soluble molecule known to be poorly absorbed when ingested. For THC edibles, most consumers report waiting 30-60 minutes for first-effects and 60-90 minutes to reach peak effects. Consumer impatience following ingestion often leads to additional dosing and overdosed results. Conversely, smoking/vaping produces first effects immediately and peak effects quickly but are increasingly in disfavor because of associated respiratory health issues. Additionally, commercial interest is burgeoning for infusing beverages and other products with THC, yet high quality methods to do so remain essentially non-existent today.

John Hollister, PBIO's Director of Sales and Marketing, commented: "The unsatisfactory long onset and full dosing delay associated with THC edibles, contrasted with the health concerns associated with smoking/vaping, continues to present a frustrating dilemma for users. Issues associated with effectively mixing THC with beverages have remained frustratingly unresolved to date. Over the past few months, we have generated a large amount evidence that our UltraShear platform definitively resolves both of these critical limitations - UltraShear is now poised to redefine the entire cannabis industry."

PBIO recently released news related to the powerful attributes of the UltraShear platform.

Consumer testing results confirmed that an UltraShear nanoemulsion THC oral spray delivered first effects in 1-10 minutes (average 3-5 minutes) and peak effects as early as 15 minutes. These first effects are up to 5-fold faster than current non-UltraShear processed THC edibles.
Early data from an-ongoing, expanded marketing study using UltraShear-processed THC correlated well with the earlier study results, again showing lightning quick speed to initial effects with UltraShear processed THC edibles.
A leading cannabis academic is expected to publish study results of UltraShear-processed CBD in a peer-reviewed journal soon, demonstrating superiority in speed of action and total bioavailability over existing edible products.
UST-processed nanoemulsions have remained stable at room temperature in excess of 24 months.
PBI is offering a limited number of 3-year, exclusive, statewide licenses to their patented UltraShear technology platform for preparing THC nanoemulsions. Processing equipment (BaroShear units) will be custom-manufactured for each Licensee. Each exclusive license will be for a single US state. The Licensee will pay an up-front license fee plus the cost to build the custom BaroShear equipment that will be placed in their facility. The resulting BaroShear equipment will be under a no-cost 3-year lease. Following the initial lease period, each Licensee will have a first opportunity right to negotiate an extension to their exclusive license. The Company plans to offer a broad-based "lease and license" program for the BaroShear equipment for THC applications on a non-exclusive basis in approximately two years. When available, no BaroShear systems will be offered for THC processing in any state that has already been designated "Exclusive" through the Early Access Program.

Parties interested in participating in this nano-THC Exclusive and Early Access Program should contact John Hollister or Ken Micciche at Pressure BioSciences.

[MaunawiliBoy]

I'm thinking the 10M loan/equity conversion is being sold off to fund this tolling station/manufacturing relationship. Otherwise, where is the $ coming from to move forward with this major PBIO strategic move? Sell off 1M shares/keep 4M shares. 4M shares rise to $5.00/shr. Who is the mystery donor? It would have to be someone within the inner circle of PBIO if my hunch is correct.

[Louied91]

$PBIO Pressure BioSciences Announces Expansion into Strategic Manufacturing Facilities with Premier Process Technologies Company, Artisan Industries

https://www.accesswire.com/749751/Pressure-BioSciences-Announces-Expansion-into-Strategic-Manufacturing-Facilities-with-Premier-Process-Technologies-Company-Artisan-Industries

Agreement Between Leading Companies in High-Pressure and Process Engineering/Equipment

Technologies Will Deliver Immediate Upgrade to PBIO's Manufacturing Capacity. Agreement Also

Offers Potential for Long-Term Equipment Manufacturing and Supply Relationship.

SOUTH EASTON, MA / ACCESSWIRE / April 18, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a global leader in the development and sale of broadly enabling, high-pressure-based equipment, consumable products, and specialty services to the life sciences field and Artisan Industries, Inc. ("Artisan"), a worldwide leader in providing purification and separation technologies for the process industries, today announced a strategic agreement between the companies.

The agreement focuses on two highly important areas: (i) PBIO will rent space and ancillary support in Artisan's state-of-the-art facilities, which will dramatically increase PBIO's manufacturing capacity for servicing the needs of its growing portfolio of Ultra Shear Technology™ ("UltraShear™ or UST™")-based nanoemulsion clients; and (ii) the relationship is expected to facilitate discussions between the companies towards an agreement that would secure Artisan as the exclusive manufacturer of PBIO's revolutionary UltraShear equipment (the "BaroShear™" line of products).

Mr. Richard T. Schumacher, President and CEO of PBIO, said: "We are excited to have reached an agreement on a leap forward in our manufacturing capacity, capabilities, and strategy that allows us to quickly transition from small, pilot scale lots for test markets (limitation of our current facilities) into large-scale servicing of UltraShear toll manufacturing contracts. We expect that this transition will be completed over the next 30 days. We will also be actively exploring the potential for this relationship to produce an equipment manufacturing partnership, one that can accelerate our execution in scaling large UltraShear partners into our lease-and-license business model for their in-house manufacturing capacity, beginning in 2024."

Mr. Schumacher continued: "This significant expansion of our manufacturing capacity comes at a perfect time, as we are putting the finishing touches on a wide-ranging agreement with cannabis industry leader John Westlake, owner of Canopy CBD Farms. Once executed, John will become the master distributor for all of PBI's hemp-derived cannabis businesses for North America. In this role, we believe John is going to keep PBIO super busy fulfilling product contracts that he will very quickly be bringing to PBIO, as he has the most extensive list of cannabis contacts many of us have ever seen!"

PBIO will continue to accept contracts for toll processing of customer's nanoemulsions requirements for the foreseeable future. Beginning in 2024, PBI's business plan will add a lease and license model, whereby the Company will be placing UltraShear equipment in the hands of customers at the cost of a monthly lease payment plus a toll/royalty rate on the output of the UST equipment. Under this growth strategy, the Company believes it may need hundreds or thousands of instruments over the coming years. The UST System contains a number of unique and complex designs and components; Artisan has an impressive history of innovation, professional manufacturing, and quality management - making them a natural and ideal choice for a prospective equipment building contract.

Mr. Tim L. Davis, President and CEO of Artisan, commented: "At Artisan, we have a deep history and appreciation for technology innovation and effective design implementation. We have monitored the emergence of the nanoemulsions industry and the struggles of multiple existing technologies in attempting to serve the enormous opportunities that exist in the marketplace for nanoemulsions. PBIO has produced a compellingly powerful, robust, reliable, adaptable, and economically scalable technology platform for the delivery of nanoemulsion solutions to capably serve the customers spanning these targeted industries. We are proud and excited to have this opportunity to work with a visionary technology innovator and the seasoned corporate leadership team at PBIO. We are also excited about the possibility of developing a strategic relationship with PBIO as the manufacturer of their revolutionary UltraShear nanoemulsion processing equipment."

Mr. Jeffrey N. Peterson, PBIO's Chairman, summarized: "Newly minted with chemical engineering degrees out of MIT in the 1970's, I had the privilege of working with innovative new process equipment designed by Artisan Industries in my early career in advanced engineering materials businesses. I was highly impressed with the quality, engineering, and performance of their designs on some very challenging product processing problems. It is a truly a serendipitous delight to come full circle in welcoming Artisan Industries as our new collaborator, at this pivotal growth inflection moment in the trajectory of Pressure BioSciences. I have great confidence in the incredibly capable and professional team at Artisan Industries."

[MaunawiliBoy]

Nice way to end Q4 22 with relevant UST derived revenues and stocking up on inventory for future PBI Agrichem sales. There must be some eminent POs in the Agrichem sales pipeline. I hope it won't take 3 1/2 months to see Q1 23 earnings, but an all time record Q revenue in the company's history is a good way to start the new year!

[Louied91]

$PBIO Pressure BioSciences, Inc. Reports Q4 and FY 2022 Financial Results, Provides Business Update, and Offers Guidance for a Strong 2023

https://www.accesswire.com/749226/Pressure-BioSciences-Inc-Reports-Q4-and-FY-2022-Financial-Results-Provides-Business-Update-and-Offers-Guidance-for-a-Strong-2023

Company Pivots Strongly into Revolutionary UltraShear Platform, Achieving Measurable Progress and Traction, Including Expected Record Revenue in Q1 2023

Investor Call Scheduled for Tuesday, April 18, 2023 at 4:30 p.m. ET

SOUTH EASTON, MA / ACCESSWIRE / April 14, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a global leader in the development and sale of broadly enabling, high-pressure-based products and services to the life sciences and other industries, reported financial results for the fourth quarter and fiscal year ended December 31, 2022, provided a business update, and offered guidance for a strong 2023, beginning with record revenue in the 2023 first quarter.

Financial Results: Q4 2022 vs. Q4 2021 (rounded to nearest thousand, except EPS)

Total revenue for Q4 2022 was $607,000 compared to $315,000 for Q4 2021, an increase of 93%.
Instrument sales for Q4 2022 were $230,000 compared to $116,000 for Q4 2021, an increase of 98%.
Consumable sales for Q4 2022 were $92,000 compared to $83,000 for Q4 2021, an increase of 11%.
PBI Agrochem subsidiary sales in Q4 2022 were $71,000 compared to $12,000 for Q4 2021, an increase of 500%.
Operating loss for Q4 2022 was $1,546,000 compared to $1,221,000 for Q4 2021, an increase of 27%, including an increase in PBI Agrochem inventory reserves of $640,000.
Basic and diluted net loss per share was $(0.38) for Q4 2022, improved from $(0.57) for Q4 2021.
Financial Results: FY 2022 vs. FY 2021 (rounded to nearest thousand, except EPS)

Total revenue for 2022 was $1,729,000 compared to $2,002,000 for 2021, a decrease of 14%.
Instrument sales for 2022 were $724,000 compared to $1,047,000 for 2021, a decrease of 31%.
Consumable sales for 2022 were $257,000 compared to $274,000 for 2021, a decrease of 6%.
PBI Agrochem subsidiary sales in 2022 were $165,000 compared to $29,000 for 2021, an increase of 466%.
Operating loss for 2022 was $4,898,000 compared to $4,185,000 for 2021, an increase of 17%, including an increase in our PBI Agrochem inventory reserves of $640,000.
Basic and diluted net loss per share was $(1.68) for 2022, improved from $(3.42) for 2021.
Director of Sales and Marketing for PBI, Mr. John B. Hollister, commented: "Impacts of the Covid pandemic supply chain disruptions and economic gyrations undeniably challenged the full year results, while PBI was also deliberately executing on our announced pivot of resources and strategic focus onto our UltraShear Technology ("UST") platform. Nonetheless, Q4 of 2022 demonstrated a strong rebound in our traditional PCT platform investments, providing welcome underpinning to the revenue growth architecture we have been building for UST in 2023 and beyond, in our march towards significantly increased revenue and profitability."

2023 Operational and Technical Highlights:

Major progress in resolving UltraShear manufacturing capacity limitations within current facilities.
Early data from an on-going, expanded THC marketing study correlates with earlier study results: UST nano-THC oral spray delivering onset in 1-10 (mostly 3-5) minutes, compared to usual onset from typical current edibles at over 45-90 minutes.
Leading academics in cannabis research expected to publish study results of UST nanoemulsified CBD in April/May 2023, demonstrating definitive superiority in speed of action and total bioavailability over existing marketed products.
PBI planning for shipments in April against three UST CBD contracts (the $1.5M contract already announced, plus 2 new/additional contracts).
Beyond early opportunities in CBD/THD, multiple additional UST contract negotiations advancing quickly with announcements pending in cosmeceuticals and immune booster nutraceuticals.
The Company expects to release Q1 2023 results with record revenue exceeding any quarter in Company's history and is confidently advancing on announced plans for capacity expansion, balance sheet strengthening, and targeted uplist to NASDAQ or NYSE in 2023.
Mr. Richard T. Schumacher, President and CEO of PBI, added: "As we emerge from a challenging period of economic turbulence and strategic transition, our team has been executing strongly to bring our transformational UltraShear technology to bear on a series of major contract opportunities spanning diverse markets, from nutraceuticals to cosmeceuticals, food and beverages, agrochemicals, and more. We are confident that our pending Q1 2023 announcement of all-time record revenue for any quarter will be quickly superseded by our projected revenue growth through each succeeding quarter in 2023."

Mr. Jeffrey N. Peterson, PBI's Chairman, concluded: "The PBI team has demonstrated exceptional tenacity and skill in managing through revolutionary technology platform innovations, early customer cultivation, and successful product and market demonstrations. We are now positioned to secure major UltraShear processing contracts, particularly in the nutraceutical area. Beyond reaching this inflection point in revenue growth, Ric and his team have achieved a major improvement in restructuring the Company's balance sheet with the significant conversion of debt to equity recently announced. The Company remains focused on completing an up-list to NASDAQ or NYSE in 2023. We are grateful to our dedicated and patient investors and to the PBI team who have delivered us to this pivotal ascension in 2023."

[MaunawiliBoy]

Nice! PBIO showing off their pressure processing in the pharma space. All three of their platforms apply, but UST will be a game changer for PBIO and pharma. Royalties for each dose created from PBIO processing. Great to see them finally trying to build relationships into this market. They must have a few extra marketing nickels to spend for this exposure. I'm hoping to see stellar FY22 and Q4 22 financials on Monday. Thanks for posting Louied91.

[Louied91]

$PBIO - "Register with complimentary registration and join Pressure Biosciences Inc at #INTERPHEX in booth #3276!"

Register with complimentary registration and join Pressure Biosciences Inc at #INTERPHEX in booth #3276! https://t.co/jeylOpBiyy

— Pressure BioSciences (@ir_pressurebio) April 11, 2023

[MaunawiliBoy]

We should see the long awaited FY22 and Q4 22 UST related revenues by next Monday.

PRESSURE BIOSCIENCES, INC. (the “Registrant”) was unable, without unreasonable effort or expense, to file its Annual Report on Form 10-K for the year ended December 31, 2022 (the “Annual Report”) by the March 31, 2023 filing date applicable to smaller reporting companies due to a delay experienced by the Registrant in completing its financial statements and other disclosures in the Annual Report. As a result, the Registrant is still in the process of compiling required information to complete the Annual Report and its independent registered public accounting firm requires additional time to complete its review of the financial statements for the period ended December 31, 2022 to be incorporated in the Annual Report. The Registrant anticipates that it will file the Annual Report no later than April 17, 2023 (the first business day after the fifteenth calendar day following the prescribed filing date

[Louied91]

$PBIO Pressure BioSciences and NutraLife Biosciences Renew Partnership for Development and Distribution of Next Generation Nutraceuticals


https://www.accesswire.com/747936/Pressure-BioSciences-and-NutraLife-Biosciences-Renew-Partnership-for-Development-and-Distribution-of-Next-Generation-Nutraceuticals

PBIO's Patented UltraShear Nanoemulsification Platform is Centerpiece of Renewed Collaboration

SOUTH EASTON, MA / ACCESSWIRE / April 6, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a global leader in the development and sale of broadly enabling, high-pressure-based products and services to the life sciences industry, and NutraLife Biosciences (OTC Markets: NLBS) ("NLBS"), a highly-respected manufacturer and distributor of nutraceuticals primarily sold on a direct-to-consumer basis, today announced they have renewed collaborative efforts initiated four years ago. Their fresh partnership is focused on combining PBIO's Best-in-Class UltraShear Nanoemulsification platform with NLBS's highly-effective nutraceuticals product formulation, marketing, sales, and distribution capabilities. The companies have just announced their fresh collaboration agreement ("Agreement"), under which PBIO and NLBS will combine their strong, symbiotic capabilities to develop, market, and sell a higher-performing line of next generation nutraceuticals.

Nutraceuticals are typically compositions that offer either or both therapeutic and nutritional effects, including the prevention and treatment of disease (DeFelice 1996). Amongst common nutraceuticals are vitamin supplements, Green Tea Supplements, Omega-3 Fatty Acids, Probiotics and Echinacea. The global nutraceuticals market is expected to reach $991 Billion by 2030 (Research and Markets, Dec 2022).

Mr. Edgar J. Ward, President and CEO of NLBS, explained: "NutraLife is delighted to be once again working with PBIO. As we originally anticipated, their UltraShear technology platform has consistently proven to be superior to other nano technology platforms in multiple critical dimensions, including extended stability, with nearly complete effective water solubility, fast and reliable dose delivery, and vastly increased bioavailability."

Mr. Ward continued: "Their revolutionary nanoemulsion process will allow us to greatly expand and differentiate our product offerings, giving NLBS a distinct competitive advantage in the nutraceutical marketplace. The UltraShear process transforms products for greatly enhanced efficiency and effectiveness of absorption for targeted nutrients and therapeutic components, delivering the highest quality and reliable results for our consumers. The new "next generation" nutraceuticals that we plan to commercialize, utilizing PBIO's innovative UltraShear platform, will be marketed and distributed through our expansive existing network of customers, on-line and retail distribution channels."

Mr. Richard T. Schumacher, President and CEO of PBIO, expanded: "Our UltraShear nanoemulsions platform has left initial collaborators across diverse markets awestruck over the potency and economic efficiencies that we can deliver to their customers and to their bottom line. Our priority has been to select partners who have the existing networks and infrastructure to "hit the ground running" with the uniquely differentiated, superior product opportunities that we offer and enable for them. Edgar and his team at NLBS are precisely what we seek - ready to leverage their extensive existing customer base and market channels to achieve early and rapidly scaling sales traction for innovative and re-engineered products across the nutraceuticals product frontier. In particular, they have been seeking a truly effective nano-CBD tincture solution - and we have that that product already developed and well proven in the hands of independent external experts."

As previously disclosed, PBIO initiated important bioavailabity studies in both academic and commercial settings over the past year in an effort to support its claim that their revolutionary UltraShear technology platform is a "Best-in-Class" nanoemulsion processing method worldwide. The Company is expecting results from at least one of these on-going studies to be published in a peer-reviewed journal in the coming weeks.

Mr. Schumacher concluded: "Edgar and his team had the technical sophistication to understand and appreciate the power and potential of our UltraShear technology earlier than others, and our teams are now enthusiastically collaborating on several remarkable new product introductions. We expect these breakthrough innovative nutraceutical products to contribute incremental revenues in the millions of dollars for both PBIO and NLBS over the coming years, with substantial revenues for both companies beginning in 2023."

[Louied91]

$PBIO Pressure BioSciences Reports Fresh Sales Momentum for PBI Agrochem


https://www.accesswire.com/746165/Pressure-BioSciences-Reports-Fresh-Sales-Momentum-for-PBI-Agrochem

PBI Agrochem Ships and Bills Initial $130,000 Eco-Friendly Agrochem Order in New Demand Pipeline

SOUTH EASTON, MA / ACCESSWIRE / March 28, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a global leader in the development and sale of broadly enabling, high-pressure-based products and services to the life sciences and other industries, and its wholly-owned subsidiary PBI Agrochem, Inc. announced it has shipped and billed an initial $130,000 order for its potent, environmentally-responsible nematode control product. The Company also announced that its newly-developed sales channel has provided confidence that an ongoing and growing pipeline of demand is expected to follow for this and other eco-friendly products in the Company's portfolio.

Global population growth is building inexorable demand for increased food production - while simultaneously, the world is awakening to the challenges and imperatives of environmental sustainability. While usage is soaring for traditional production-boosting synthetic pesticides and fertilizers (despite the persistent environmental threat they create through glacially-slow degradation of toxic components), these older synthetic products are beginning to be eclipsed by new generations of naturally-sourced substances providing potent but environmentally-responsible, eco-friendly agrochemicals.

Mr. John B. Hollister, Director of Sales and Marketing at PBI, explained: "It has required considerable time and effort for us to build fresh relationships and sales channels to serve this burgeoning new market opportunity, which is pivotal to the economic and health trajectories of our planet. As we have begun to establish the PBI Agrochem name in this exciting growth market, we have been consistently told that our thoughtfully organically-sourced and produced eco-friendly agrochem solutions are far superior in potency and value than their older, more expensive, traditional synthetic competitors."

Mr. Hollister continued: "This incremental $130,000 order from a new business sector has arrived on top of a remarkably strong 1st Quarter 2023 performance to date. Coupled with our recently announced $1.5 Million dollar order for UltraShear toll production of bulk concentrates for CBD products, and further orders now developing in hemp-derived cannabinoids, cosmeceuticals, nutraceuticals, and food/beverage markets, PBI is clearly positioned for commercial take-off during 2023."

New and old generations of agrochemicals face common challenges in getting a variety of oily (not soluble in water) active ingredients to become effectively absorbed and thus "bioavailable" within their targeted plant species, whose biochemistry is mostly water-based. PBI's Ultra Shear Technology™ ("UST™" or "UltraShear™") nanoemulsification platform, which can make oils effectively soluble in water, is a strategic "change agent" technology platform for this market sector and should enable more effective agrochemical dosing while reducing the quantities of expensive active ingredients required. Pesticides, used to control insects that damage crops and severely limit production, are projected to grow in worldwide sales from $84.5 billion in 2019 to $131 billion by 2023. Fertilizers, used to replenish soil with essential nutrients required for better crop growth and production, are expected to achieve global sales of approximately $255 billion by 2027."

Mr. Richard T. Schumacher, President and CEO of PBI, commented: "This new opportunity offers great strategic impact as an ideal demonstration market for the game-changing impact of our UltraShear nanoemulsions platform on a global industry poised and needy of the benefits we are preparing to deliver. We have already successfully nanoemulsified neem oil and are beginning to study the positive impact that UltraShear processing can have on additional eco-friendly agrochem products."

Mr. Schumacher concluded: "We continue to work relentlessly on funding our technology and inventory scale-up for growth, while improving our Balance Sheet, and positioning PBIO for a planned up-listing to NASDAQ or NYSE during 2023. This is certainly an exciting moment for all of our stakeholders and for the array of global markets that UltraShear is poised to revolutionize. And as good as things are now, we strongly believe they will only get better as we move further into 2023."

[noshorthere]

Correction: They got a development contract that they hope will get them $1.5M this year from a company with 16 stores and $413,570 total revenue.

Hope springs eternal, but when divorced from reality it is little more than illusion.

However, “The best predictor of future behavior is relevant past behavior.” ....Dr.Phil

[Louied91]

$PBIO Pressure BioSciences Receives $1.5M Contract for UltraShear Nanoemulsified CBD

https://www.accesswire.com/745130/Pressure-BioSciences-Receives-15M-Contract-for-UltraShear-Nanoemulsified-CBD

CBD Supply MD, a Leading Maryland-Based CBD Retailer, to Introduce PBIO's UltraShear Processed, Best-in-Class Nanoemulsified CBD Products Across the Multi-State Mid-Atlantic Region

SOUTH EASTON, MA / ACCESSWIRE / March 22, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a global leader in the development and sale of broadly enabling, high-pressure-based products and services to the life sciences and other industries, and CBD Supply MD, one of the largest and best-known retail suppliers of CBD products in the multi-state mid-Atlantic region, today announced the execution and launch of a manufacturing and distribution agreement (the "Agreement"). Under the terms of the Agreement, PBIO will supply CBD Supply MD with the Company's UltraShear™ optimized nanoemulsions of CBD in a best-in-class, long-term stable, and highly bioavailable CBD Topical Spray, formulated for ideal effectiveness and optimal potency, addressing consumer's diverse CBD objectives. The Agreement is expected to generate over $1.5 Million in revenue for PBIO during 2023, including nearly $250,000 in the second quarter.

The Agreement defines four phases of product development and commercialization for a custom-formulated topical spray of hemp-derived, UltraShear nanoemulsified CBD designed for extremely rapid absorption and effectiveness and for efficient high potency delivery of the CBD active material in each dose. All ingredients used in the manufacture of the Company's nano-CBD are sourced from naturally-occurring, plant-based origins. Phase I of the Agreement is underway and provides for an initial shipment of 850 vials (30ml. volume @ 40mg/ml) of UltraShear-nanoemulsified CBD to CBD Supply MD by mid-April 2023.

Mr. Keith E. Manley, Co-founder of CBD Supply MD, commented: "Partnerships like this don't happen overnight - and for good reason. It takes a lot of time and hard work to ensure that both parties are a good fit, now and in the future. The game-changing UltraShear processed product line we are bringing to market fills a legitimate, long-awaited, and sorely unfulfilled need of our customers and the market."

Mr. Manley continued: "This past year I've gotten to know Ric and the PBIO team very well. As CEO of CBD Supply MD, I review thousands of products a year. Without hesitation, I can say the hemp-derived nano-CBD developed by Pressure BioSciences is a true game-changer. Their best-in-class UltraShear processed nano-CBD manifests unmatched bioavailability and long-term shelf stability that is unparalleled in the industry. This is the first of many UltraShear nanoemulsified products we plan to bring to market with our new partner PBIO. As excited as this makes me, I know that my enthusiasm will pale in comparison to the benefits our customers will receive."

Mr. John B. Hollister, Director of Sales and Marketing at PBI, observed: "CBD Supply MD is a rapidly-growing and highly respected market leader, with one of the largest established customer bases in the mid-Atlantic region. We are excited that their customers will now have the opportunity to benefit from our best-in-class nano-CBD product that has been manufactured with our patented UltraShear processing platform. Results achieved to date with UltraShear-processed cannabis products gives us tremendous confidence that word will spread very quickly about the absorption speed and effectiveness of our UltraShear-enabled products, as well as how quickly and effectively they address and satisfy the needs of the customer. We look forward to developing multiple additional product formulations with CBD Supply MD beyond this substantial initial $1.5M contract."

Mr. Richard T. Schumacher, PBIO's President and CEO summed up: "Our diverse work on UltraShear nanoemulsion processing across nutraceutical, cosmeceutical, pharmaceutical, food/beverage, and agrochemical markets has generated an exciting array of developing commercial opportunities for PBI. We have foreshadowed a plethora of contracts anticipated with many clients requiring nanoemulsion product development, demonstrations, toll manufacturing services, and eventual lease/license agreements around our patented and revolutionary UltraShear technology platform. We are honored to welcome this new partnership with CBD Supply MD - a highly respected retail sales leader in the cannabis marketplace, especially in CBD products. Additional pending agreement announcements, coupled with continued positive improvements in our financing activities, balance sheet, and capitalization table are helping us accelerate PBIO's path forward to a planned uplist to either the NASDAQ/ NYSE stock exchange later this year. Finally, as much as we are deeply excited about our achievements to date, we truly believe that the best is yet to come."

[velcro]

I would think the actual details must be spelled out in a SEC Report.
This unidentified Investor converted only 50% of their debt holdings.
Anyway, moving in the right direction.

[Louied91]

$PBIO Pressure BioSciences Announces the Exchange of Over $10 Million of Debt into Equity

https://www.accesswire.com/741423/pressure-biosciences-announces-the-exchange-of-over-10-million-of-debt-into-equity

Company's Largest Investor Exchanges First Seniority Debt into Non-Secured Equity at 38% Above-Market Price, Expressing Confidence and Support

SOUTH EASTON, MA / ACCESSWIRE / March 1, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a global leader in the development and sale of broadly enabling, high-pressure-based products and services to the life sciences and other industries, today announced that the Company's largest shareholder has exchanged over $10 million of senior secured debt into unsecured preferred stock. The debt being converted is comprised of convertible promissory notes, accrued and unpaid interest on all promissory notes issued to the investor since November 2019, plus accrued and unpaid dividends on the Company's Series AA Convertible Preferred Stock purchased by the investor since May 2018.

The $10+ million of debt exchanged into equity represents over 50% of the total debt currently owed to the Investor by the Company and represents over 30% of the Company's total outstanding debt held by all investors through February 2023 via (i) convertible promissory notes; (ii) accrued and unpaid interest on convertible promissory notes; and (iii) accrued and unpaid dividends earned from investments in the Company's Series AA Convertible Preferred Stock financing. The exchange of debt to equity was consummated at a value of $2.50 per share of Common Stock, which is an approximate 38% premium over the Company's recent open market valuation.

The Company recently announced a number of significant achievements and collaborations, particularly related to its revolutionary Ultra Shear™ Technology ("UltraShear™") platform for its "best-in-class" nanoemulsion processing. Among these are: (i) the development of "next generation" anti-aging skincare and hair regrowth products with partner Dr. Denese SkinScience; (ii) the development of a sports performance/recovery drink with NBA legend Isiah Thomas' One World Products (OTCQB: OWPO); and (iii) the release of dramatic consumer testing results, indicating that PBIO's UltraShear platform is forging a game-changing future for the cannabis, nutraceuticals, and supplements industries.

Mr. Richard T. Schumacher, President and CEO of PBIO, commented: "The PBIO Team is delighted with the strong recent progress in multiple aspects of our business. We are redesigning our production facilities, adding to our team, strengthening our core capabilities, filing additional UltraShear patents, building instrument inventories, and expanding our list of existing and prospective 2023 customers. We are engaging deeper into building strong strategic partnerships with key companies and individuals, including several billion-dollar companies who are global best-in-class players in priority markets targeted for explosive growth. In addition, we have begun forging stronger relationships with multiple strategic and retail investors."

Mr. Schumacher continued: "It has been a long time since I've seen and felt such excitement, enthusiasm, and confidence in the future of PBIO within our shareholder base. We believe this announced conversion of debt into equity is only the beginning of continued strengthening in our financial position and outlook. We are in discussions with other large shareholders who have expressed similar interest in supporting the Company through continuing improvements in our balance sheet, by exchanging additional millions of dollars of debt into equity, following the confidence and leadership demonstrated by the Company's long-standing, largest investor. We anticipate additional similar announcements in the coming weeks."

Mr. Jeffrey N. Peterson, Chairman of PBIO, added: "The PBIO team has demonstrated tremendous dedication and execution in converting their vision and planning for our patent-protected nanoemulsions breakthrough technology into a proven reality that is already demonstrating the transformational power to restate the basis for competition in multiple multi-billion-dollar markets, spanning nutraceuticals, cosmeceuticals, pharmaceuticals, food and beverage, agrochemicals, and industrial markets. We are deeply appreciative for the patience and confidence demonstrated by our largest investor in this pivotal decision, and to all our investors who have delivered us to this inflection point, as we accelerate forward through commercialization, growth, capacity expansion, further capitalization, uplist to NASDAQ/NYSE, and our expected transition to profitability during the next year."

[Sox24]

https://thestreetreports.com/pbio-ceo-ric-schumacher-discusses-stock-price-company-updates-and-positive-forecast-on-the-street-reports-podcast-listen-now

[MaunawiliBoy]

Did EMGE report PBIO Q4 revenues? 400K

[Sox24]

Watch this stock. Great opportunity undervalued. Do some DD look at the developments and prs. Revenues will not be an issue. Accumulate.

[velcro]

Will the Chinese knockoffs sell around the world?
I hope PBIO knows what they are doing.

[Louied91]

$PBIO Pressure BioSciences Receives Record Nearly $600,000 Order for 16 PCT Instruments

https://www.accesswire.com/737686/pressure-biosciences-receives-record-nearly-600000-order-for-16-pct-instruments

Largest Single Order in Company's History was Prepaid as New Chinese Distributor Comes Online;

Adds to Revenue Strength Also Building Across PBI's UltraShear Nanoemulsions Platform

SOUTH EASTON, MA / ACCESSWIRE / February 1, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a global leader in the development and sale of broadly enabling, high-pressure-based products and services to the life sciences and other industries, today announced entrance into an exclusive distribution agreement for the People's Republic of China ("Agreement") with PRS International Trade (Shanghai) Co., Ltd. ("PRS International").

Reflecting confidence built upon PBIO's long investment in developing worldwide market support for the Company's Pressure Cycling Technology ("PCT") platform, PRS International prepaid for the entire purchase of 16 Barocycler EXT units for a total of nearly $600,000, with a commitment to purchase additional units and related consumables before the end of 2023. This historic purchase of PBIO's original high-pressure technology instruments comes on the back of a surge in purchase orders for all product categories of the Company's pressure-based instruments and consumables.

Director of Sales and Marketing John B. Hollister commented, "We believe this purchase of a record number of Barocycler EXT instruments, together with strong worldwide indications of purchase plans for additional non-PCT instruments and consumables, indicates that China and the rest of the life sciences world is finally emerging from under the economic cloud of COVID. We expect first quarter 2023 sales to benefit from the initial shipment of up to five Barocycler EXT instruments to China, from the surge in orders we are experiencing in our other pressure-based instrument areas (e.g., Barocyclers, HUB pressure generators, and cell disruptors), and from our recently opened UltraShear™ nanoemulsions tolling services. Adding to this excitement, we had a few expected sales in 2022 slip into 2023 due to supply chain issues. The net effect is that we are having a terrific first quarter, which we believe will continue to strengthen throughout 2023 and beyond."

Richard T. Schumacher, President and CEO, expanded: "We have been focusing the majority of our efforts on the launch of our revolutionary UltraShear nanoemulsions processing platform, which we expect will lead to ramping revenue in 2023. Additionally, our long-term investment in building broad-based market support for our line of pressure-based instruments continues to pay off with growing penetration and adoption for our initial high-pressure technology platforms and application areas. Our commitment to supporting this key area of our business remains unwavering. We are honored and humbled by the large, prepaid order from PRS International, and we are delighted to be in a position to reinvest our strengthening technical and financial foundation in support of our next generation UltraShear nanoemulsions technology platform that we believe will be manifesting strong commercial traction starting in this quarter."

Jeffrey N. Peterson, Chairman of PBIO, observed, "Ric and his team were visionaries in building strong scientific support and credibility in the Company's initial PCT platform technology and applications areas. While we see market opportunities growing into the tens of millions of dollars for this platform in the coming years, our strategic focus has appropriately advanced onto our BaroFold and now our UltraShear platforms. BaroFold is an applications arena that we believe offers future potential growth that could be multiples greater for PBIO than the PCT product line. However, our investment in the development of the UltraShear™ platform, for the production of extremely stable and bioavailable nanoemulsions of oil-soluble active molecules for effective delivery into humans, animals, and plants, is a game-changing technology that we believe offers PBI opportunities into the hundreds of millions of dollars, if not more, as it re-defines the basis of competition in multiple multi-billion dollar industries, from pharmaceuticals to nutraceuticals, cosmeceuticals, food/beverage, agrochemicals, and more."

[Louied91]

$PBIO $OWPC Pressure BioSciences and One World Products Announce Partnership in Development of CBD-Nanoemulsion Sports Performance/Recovery Drinks

https://www.accesswire.com/737034/pressure-biosciences-and-one-world-products-announce-partnership-in-development-of-cbd-nanoemulsion-sports-performancerecovery-drinks

NBA Legend Isiah Thomas Leads Effort to Innovate and Deliver Next Generation Sports Drinks

SOUTH EASTON, MA / ACCESSWIRE / January 27, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a global leader in the development and sale of broadly enabling, high-pressure-based products and services to the life sciences industry, and One World Products, Inc. (OTCQB: OWPC) ("OWPC"), the largest Black-controlled, fully-licensed hemp and cannabis producer in Colombia, today announced they have entered into an active collaboration agreement ("Agreement") under which the two companies will combine their strong, symbiotic capabilities to develop an innovative line of next generation sports performance/recovery drinks.

The Sports Performance/Recovery Drink Market encompasses live sports performance optimization, rapid and effective full recovery post-performance, and health and wellness areas - including immune health and antioxidant benefits. Fast delivery and uptake of therapeutic and nutritional ingredients must be made effective for the many oil-soluble active ingredients used in sports drinks. This is where PBIO's revolutionary UltraShear™ nanoemulsions platform technology is already demonstrating game-changing results across multiple major consumer market applications. The "Recovery" market has also been supported by increasing numbers of consumers who consider themselves "non-athletes" joining in the sports drink craze. Data from IRI put sales of sports/performance beverages at about $9.5 billion for 2021 (sports drink market 2021).

Isiah Thomas, Chairman and CEO of OWPC, highlighted: "This revolutionary new line of sports performance/recovery drinks will contain OWPC's premium quality CBD that has been processed into a highly stable and extremely bioavailable nanoemulsion by PBIO's patented UltraShear technology platform. This next generation CBD-nanoemulsion beverage is being designed for fast reduction of inflammation and pain, improved recovery time, and enhanced overall performance - all to be achieved quicker than any competing drink on the market today. It is being formulated to help athletes push through the tough moments of a workout or competition, and to recover more quickly afterward. In professional and even amateur sports, athletes understand the criticality of peak performance and recovery."

Mr. Thomas continued: "OWPC has been a highly sought after choice for the development of new and premium technologies for delivery of hemp and cannabis-derived products. I am excited that we have an opportunity to pair our premium quality CBD product with PBIO's proprietary, cutting-edge nanoemulsification technology to deliver a uniquely-innovative and effective product to market that we believe will offer unmatched rapid absorption and full dosing of hard-to-deliver oil-soluble ingredients - to achieve game-changing performance."

Richard T. Schumacher, President and CEO of PBIO, expanded: "Partnering with Isiah and his exceptional team at OWPC is an extraordinary opportunity for PBIO to accelerate the visibility and impact of our revolutionary UltraShear nanoemulsions platform technology. Isiah is a world-renowned figure in the world of sports and more broadly as a role model in Black-owned business leadership, and it is a privilege for our companies to team up! OWPC has become a leading producer of the highest quality and sustainably sourced hemp-derived CBD in Colombia, and is closely partnered with their government and indigenous populations. Teamed with PBIO's best-in-class nanoemulsions processing, OWPC is uniquely positioned to deliver these solutions and drive rapid recognition and acceptance across the worlds of professional and amateur sports. This is going to be exciting and, we believe, very successful!"

[Premium Stocks]

Pressure BioSciences and One World Products Announce Partnership

in Development of CBD-Nanoemulsion Sports Performance/Recovery Drinks



NBA Legend Isiah Thomas Leads Effort to Innovate and Deliver Next Generation Sports Drinks





Sports Performance/Recovery Drinks Market was estimated to have been about $9.5 Billion in 2021
One World Products (OTCQB: OWPC) is a leading producer of high quality hemp-derived CBD in Columbia
Pressure BioSciences (OTCQB: PBIO) has seven (7) issued patents covering its proprietary, cutting-edge nanoemulsification technology: UltraShear
UltraShear processed CBD has been shown to be a uniquely-innovative and effective product with unmatched rapid absorption and long-term stability
This next generation CBD-nanoemulsion beverage is being designed for fast reduction of inflammation and pain, improved recovery time, and enhanced overall performance – all to be achieved quicker than any competing drink on the market today. It is being formulated to help athletes push through the tough moments of a workout or competition, and to recover more quickly afterward.
This unique drink will contain OWPC’s high quality CBD that has been processed into a long-term stable and highly bioavailable nanoemulsion by PBI’s UltraShear technology platform
The two companies have signed a collaboration agreement that covers all of the legal and corporate issues of the partnership
The Agreement specifies that the two companies will work out specific responsibilities of each group going forward.
The partnership relies on OWPC producing and supplying their well-recognized high quality CBD and PBIO using their patented and unique UltraShear to process the CBD into their best-in-class nanoemulsions for infusion into the new sports drink
It is expected that additional oil-based ingredients will be used (vitamins, supplements, nutraceuticals) in the sports drink – all will be nanoemulsified using the PBIO UltraShear process